Posted by Michael Wonder on 04 Dec 2023
Vosoritide in achondroplasia: indication of an additional clinical benefit for children aged two and over
1 December 2023 - Two small RCTs with children of different ages together make it possible to make one statement: the new active ingredient promotes linear growth.
In an early benefit assessment, the IQWiG examined whether vosoritide benefits patients aged two and over with achondroplasia in whom the epiphyses are not yet closed.
